Observational Study of Subjects Having Routine Recurrence Screening for Bladder Cancer

The purpose of this study is to detect recurrent bladder cancer using a combination of protein and DNA biomarkers in urine

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bladder Cancer Recurrence

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

BCG Oncology, Phoenix, Arizona, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Intact bladder
Scheduled for cystoscopy for transitional cell bladder cancer recurrence screening
Urine donated prior to cystoscopy, Bladder biopsy, chemotherapy, intravesical therapy, radiation or TUR
Must be willing to sign IRB approved informed consent

Exclusion criteria

History or current diagnosis of any cancer except transitional cell bladder cancer or basal cell cancer
Known diagnosis of any autoimmune disease or HIV, HCV or HBV
History or current TB or any other active infection
Subject has gross hematuria
Receiving chemotherapy, intravesical therapy or radiation within 30 days of enrollment
Any surgery except urologic within past 30 days

Sponsors and collaborators

Lead sponsor

Predictive Biosciences

Industry

Registry information

Official study title

Phase 3 Study of Bladder Cancer Recurrence Surveillance

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: May 18, 2009
Registry last updated: Jun 8, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed